The study below explains in-depth how Hyperbaric Oxygen Therapy reduces micro coagulation, the effect of COVID-19, thought to cause most damage.
The study below explains in-depth how Hyperbaric Oxygen Therapy reduces micro coagulation, the effect of COVID-19, thought to cause most damage.
PDF:
LINK:
A clinical trial NCTO4647656, which can be found at ClinicalTrials.gov, is being conducted to study the effects of hyperbaric oxygen therapy on post COVID 19 symptoms. The main symptoms being reported are cognitive impairment, fatigue and sleep disorders. It states that there are biological indicators that play roles in the post COVID 19 syndrome such as:
HBOT is based on intermittent inhalation of 100% oxygen in a pressurized chamber under 1.5 to 3.0 ATA. All HBOT properties meet the demand of aerobic metabolism in hypoperfused regions of the body, such as the alveoli suffering from edema, low lung surfactant production, tissue inflammation, and areas of perialveolar microthrombosed capillaries found in patients with COVID-19. Besides offering better oxygen perfusion, HBOT also has anti-inflammatory and anti-coagulant actions.
The FDA has not yet approved treatments for COVID-19 and Post-COVID-19 conditions. Historically the administration has been slow to authorize these treatments due to lack of funding for trials. The medical community is heading up private trials as efficiently as possible subject to large study populations and financial barriers.
Currently, Post-COVID patients are able to access this medical treatment as an off-label indication. Consult with your doctor to see if HBOT is right for you. We have onsite physicians that you may reach out to as well.